| Nevada                                                                        |   | 87-0650264                                          |
|-------------------------------------------------------------------------------|--------|-----------------------------------------------------|
| (State                or Other Jurisdiction of Incorporation or Organization) |   | (I.R.S.                Employer Identification No.) |
|                                                                          |   |                                                |

----

**HUIFENG      BIO-PHARMACEUTICAL TECHOLOGY INC.**

**AND      SUBSIDIARIES**

**FORM      10-QSB**

**Quarter      Ended September 30, 2007**

**TABLE      OF CONTENTS**

|                     |   | **PART                  I—                  FINANCIAL INFORMATION**                                                                                                                                                               |   |     |
|--------------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|
|                     |   |                                                                                                                                                                                                                                    |   | **Page** |
| Item                  1. |   | Financial                  Statements                                                                                                                                                                                                   |   |     |
|                     |   | Unaudited                  Condensed Consolidated Balance Sheet as of September 30,                  2007                                                                                                                               |   | 2        |
|                     |   | Unaudited                  Condensed Consolidated Statements of Operations and Comprehensive                  Income                  for                  the Three and Nine Months Ended September 30, 2007 and                  2006 |   | 3        |
|                     |   | Unaudited                  Condensed Consolidated Statements of Cash Flows for the Nine Months                  Ended                  September 30, 2007 and 2006                                                                 |   | 4        |
|                     |   | Notes                  to Unaudited Condensed Consolidated Financial Statements as of                  September                  30, 2007                                                                                              |   | 5        |
| Item                  2. |   | Management’s                  Discussion and Analysis of Financial Condition or Plan of                  Operation                                                                                                                |   | 10       |
| Item                  3. |   | Controls                  and Procedures                                                                                                                                                                                                |   | 14       |
|                     |   | **PART                  II— OTHER INFORMATION**                                                                                                                                                                                   |   |     |
| Item                  1. |   | Legal                  Proceedings                                                                                                                                                                                                      |   | 15       |
| Item                  2. |   | Unregistered                  Sales of Equity Securities and Use of Proceeds                                                                                                                                                            |   | 15       |
| Item                  3. |   | Defaults                  Upon Senior Securities                                                                                                                                                                                        |   | 15       |
| Item                  4. |   | Submission                  of Matters to a Vote of Security Holders                                                                                                                                                                    |   | 15       |
| Item                  5. |   | Other                  Information                                                                                                                                                                                                      |   | 15       |
| Item                  6. |   | Exhibits                  and Reports on Form 8-K                                                                                                                                                                                  |   | 15       |
| **SIGNATURES**           |   | 16                                                                                                                                                                                                                                      |

----

**PART      I. FINANCIAL INFOMRATION**

| **ASSETS**                                                                                                                                                                      |   |                                |       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------|------------|
|                                                                                                                                                                            |   |                      |       |
| **CURRENT                ASSETS**                                                                                                                                               |   |                      |       |
| Cash                and cash equivalents                                                                                                                                   |   | $                                   | 846,145    |   |
| Accounts                receivable, net of allowances                                                                                                                      |   |                                | 1,404,201  |   |
| Inventories,                net                                                                                                                                            |   |                                | 2,258,233  |   |
| Notes                receivable                                                                                                                                            |   |                                | 133,021    |   |
| Other                assets                                                                                                                                                |   |                                | 394,997    |   |
|  Total                Current Assets                                                                                                                                       |   |                                | 5,036,597  |   |
|                                                                                                                                                                            |   |                                |            |   |
| **PROPERTY                AND EQUIPMENT, NET**                                                                                                                                  |   |                                | 3,479,920  |   |
|                                                                                                                                                                            |   |                                |            |   |
| **LAND                USE RIGHTS, NET**                                                                                                                                         |   |                                | 139,238    |   |
| **TOTAL                ASSETS**                                                                                                                                                 |   | $                                   | 8,655,755  |   |
|                                                                                                                                                                            |   |                                |            |   |
|                                                                                                                                                                            |   |                                |            |   |
| **LIABILITIES                AND STOCKHOLDERS' EQUITY**                                                                                                                         |   |                                |            |   |
|                                                                                                                                                                            |   |                                |            |   |
| **CURRENT                LIABILITIES**                                                                                                                                          |   |                                |            |   |
| Accounts                payable                                                                                                                                            |   | $                                   | 60,516     |   |
| Other                payables and accrued expenses                                                                                                                         |   |                                | 273,458    |   |
| Notes                payable                                                                                                                                               |   |                                | 287,326    |   |
| Income                tax and other tax payables                                                                                                                           |   |                                | 385,308    |   |
|  Total                Current Liabilities                                                                                                                                  |   |                                | 1,006,608  |   |
|                                                                                                                                                                            |   |                                |            |   |
| **COMMITMENTS                AND CONTINGENCIES**                                                                                                                                |   |                                | -          |   |
|                                                                                                                                                                            |   |                                |            |   |
| **MINORITY                INTERESTS**                                                                                                                                           |   |                                | 443,913    |   |
|                                                                                                                                                                            |   |                                |            |   |
| **STOCKHOLDERS'                EQUITY**                                                                                                                                         |   |                                |            |   |
| Preferred                stock, ($0.001 par value, 5,000,000 shares authorized, non issued                and                outstanding)                                       |   |                                | -          |   |
| Common                stock, ($0.018 par value, 100,000,000 shares authorized, 18,466,169                shares                issued and outstanding as of September 30, 2007) |   |                                | 332,388    |   |
| Additional                paid-in capital                                                                                                                                  |   |                                | 8,020,066  |   |
| Retained                earnings (deficit)                                                                                                                                 |   |                                |            |   |
| Unappropriated                                                                                                                                                             |   |                                | (1,786,078 | ) |
| Appropriated                                                                                                                                                               |   |                                | 82,925     |   |
| Accumulated                other comprehensive income                                                                                                                      |   |                                | 555,933    |   |
|  Total                Stockholders' Equity                                                                                                                                 |   |                                | 7,205,234  |   |
|                                                                                                                                                                            |   |                                |            |   |
| **TOTAL                LIABILITIES AND STOCKHOLDERS' EQUITY**                                                                                                                   |   | $                                   | 8,655,755  |   |

----

|                                                                                                              |   | For                the Three Months Ended September 30, 2007 |       | For                the Three Months Ended September 30, 2006 |   | For                the Nine Months Ended September                30, 2007 |   | For                the Nine Months Ended September                30, 2006 |       |
|-------------------------------------------------------------------------------------------------------------------|--------|--------------------------------------------------------------|------------|--------------------------------------------------------------|--------|----------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------|------------|
|                                                                                                              |   |                                                         |       |                                                         |   |                                                                       |   |                                                                            |       |
| **NET                SALES**                                                                                      |   | $                                                            | 1,945,975  |                                                         |   | 816,093                                                                    |   |                                                                            | 4,954,122  |   |   | 2,378,788 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **COST                OF SALES**                                                                                  |   |                                                         | (1,430,755 | )                                                            |   | (672,441                                                                   | )      |                                                                            | (3,462,644 | ) |   | (1,963,992 | ) |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **GROSS                PROFIT**                                                                                   |   |                                                         | 515,220    |                                                         |   | 143,652                                                                    |   |                                                                            | 1,491,478  |   |   | 414,796 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **OPERATING                EXPENSES**                                                                             |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| Selling                expenses and distribution expenses                                                         |   |                                                         | 32,523     |                                                         |   | 20,897                                                                     |   |                                                                            | 76,219     |   |   | 105,342 |   |
| General                and administrative expenses                                                                |   |                                                         | 72,875     |                                                         |   | 47,001                                                                     |   |                                                                            | 207,635    |   |   | 157,120 |   |
| Depreciation                and amortization                                                                      |   |                                                         | 11,714     |                                                         |   | 11,482                                                                     |   |                                                                            | 35,532     |   |   | 34,463 |   |
| Total                Operating Expenses                                                                           |   |                                                         | 117,112    |                                                         |   | 79,380                                                                     |   |                                                                            | 319,386    |   |   | 296,925 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **INCOME                FROM OPERATIONS**                                                                         |   |                                                         | 398,108    |                                                         |   | 64,272                                                                     |   |                                                                            | 1,172,092  |   |   | 117,871 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **OTHER                INCOME (EXPENSE)**                                                                         |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| Interest                income                                                                                    |   |                                                         | 6,002      |                                                         |   | 13,194                                                                     |   |                                                                            | 19,869     |   |   | 39,095 |   |
| Interest                expense                                                                                   |   |                                                         | (7,568     | )                                                            |   | (4,297                                                                     | )      |                                                                            | (25,327    | ) |   | (4,354 | ) |
| Other                income                                                                                       |   |                                                         | 6,077      |                                                         |   | 15,375                                                                     |   |                                                                            | 39,497     |   |   | 34,275 |   |
| Total                Other Income, net                                                                            |   |                                                         | 4,511      |                                                         |   | 24,272                                                                     |   |                                                                            | 34,039     |   |   | 69,016 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **INCOME                FROM OPERATIONS BEFORE TAXES AND MINORITY                INTEREST**                       |   |                                                         | 402,619    |                                                         |   | 88,544                                                                     |   |                                                                            | 1,206,131  |   |   | 186,887 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **INCOME                TAX EXPENSE**                                                                             |   |                                                         | (66,824    | )                                                            |   | (18,060                                                                    | )      |                                                                            | (199,981   | ) |   | (55,786 | ) |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **MINORITY                INTERESTS**                                                                             |   |                                                         | (2,649     | )                                                            |   | 6,510                                                                      |   |                                                                            | 25,826     |   |   | 19,204 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **NET                INCOME**                                                                                     |   |                                                         | 333,146    |                                                         |   | 76,994                                                                     |   |                                                                            | 1,031,976  |   |   | 150,305 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **OTHER                COMPREHENSIVE INCOME**                                                                     |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| Foreign                currency translation (loss) gain                                                           |   |                                                         | 98,962     |                                                         |   | (262                                                                       | )      |                                                                            | 252,634    |   |   | 96,841 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **COMPREHENSIVE                INCOME**                                                                           |   | $                                                            | 432,108    |                                                         | $      | 76,732                                                                     |   | $                                                                               | 1,284,610  |   | $ | 247,146 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| **Net                income per share - basic and diluted**                                                       |   | $                                                            | 0.02       |                                                         | $      | 0.01                                                                       |   | $                                                                               | 0.06       |   | $ | 0.01 |   |
|                                                                                                              |   |                                                         |            |                                                         |   |                                                                            |   |                                                                            |            |   |   |  |   |
| Weighted                average number of shares outstanding during the period - basic and                diluted |   |                                                         | 18,466,169 |                                                         |   | 16,466,169                                                                 |   |                                                                            | 18,466,169 |   |   | 16,466,169 |   |

----

|                                                                                    |   | For                          the Nine       |       | For                          the Nine       |   |
|-----------------------------------------------------------------------------------------|--------|---------------------------------------------|------------|---------------------------------------------|--------|
|                                                                                    |   | Months                          Ended       |       | Months                          Ended       |   |
|                                                                                    |   | September                          30, 2007 |       | September                          30, 2006 |   |
| **CASH                          FLOWS FROM OPERATING ACTIVITIES**                       |   |                                        |       |                                        |   |
| Net                          income                                                |   | $                                           | 1,031,976  |                                        | $      | 150,305 |   |
| Adjusted                          to reconcile net income to net cash provided by  |   |                                        |            |                                        |   |  |   |
|  (used                          in) operating activities:                          |   |                                        |            |                                        |   |  |   |
| Allowance                          for doubtful accounts - accounts receivable          |   |                                        | (35,781    | )                                           |   | - |   |
|  Depreciation                          and amortization - cost of sales            |   |                                        | 242,686    |                                        |   | 167,732 |   |
|  Depreciation                          and amortization                            |   |                                        | 35,532     |                                        |   | 34,463 |   |
|  Minority                          interest                                        |   |                                        | (25,826    | )                                           |   | (19,204 | ) |
| Changes                          in operating assets and liabilities               |   |                                        |            |                                        |   |  |   |
|  (Increase)                          decrease in:                                  |   |                                        |            |                                        |   |  |   |
|  Accounts                          receivable, net                                 |   |                                        | (211,182   | )                                           |   | 211,053 |   |
|  Inventories                                                                       |   |                                        | (1,619,088 | )                                           |   | (579,778 | ) |
|  Due                          from stockholders                                    |   |                                        | 24,580     |                                        |   | 10,089 |   |
|  Other                          assets                                             |   |                                        | 611,801    |                                        |   | (102,590 | ) |
|  Increase                          (decrease) in:                                  |   |                                        |            |                                        |   |  |   |
|  Accounts                          payable                                         |   |                                        | 6,004      |                                        |   | (77,141 | ) |
|  Other                          payables and accrued expenses                      |   |                                        | 126,322    |                                        |   | 32,905 |   |
|  Income                          tax and other taxes payable                       |   |                                        | 162,444    |                                        |   | 52,215 |   |
|  Due                          to stockholders                                      |   |                                        | -          |                                        |   | (1,250 | ) |
|  Net                          cash provided by (used in) operating activities      |   |                                        | 349,468    |                                        |   | (121,201 | ) |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **CASH                          FLOWS FROM INVESTING ACTIVITIES**                       |   |                                        |            |                                        |   |  |   |
| Decrease                          in notes receivable                                   |   |                                        | 325,701    |                                        |   | - |   |
| Purchase                          of property and equipment                        |   |                                        | (287,898   | )                                           |   | (156,970 | ) |
| Net                          cash provided by (used in) investing activities            |   |                                        | 37,803     |                                        |   | (156,970 | ) |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **CASH                          FLOWS FROM FINANCING ACTIVITIES**                       |   |                                        |            |                                        |   |  |   |
| Proceeds                          from notes payable                               |   |                                        | 31,266     |                                        |   | 300,000 |   |
| Net                          cash provided by financing activities                      |   |                                        | 31,266     |                                        |   | 300,000 |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **EFFECT                          OF EXCHANGE RATES ON CASH**                           |   |                                        | (35,860    | )                                           |   | 21,102 |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **NET                          INCREASE IN CASH AND CASH EQUIVALENTS**                  |   |                                        | 382,677    |                                        |   | 42,931 |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **CASH                          AND CASH EQUIVALENTS AT BEGINNING OF PERIOD**           |   |                                        | 463,468    |                                        |   | 89,108 |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **CASH                          AND CASH EQUIVALENTS AT END OF PERIOD**                 |   | $                                           | 846,145    |                                        | $      | 132,039 |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| **SUPPLEMENTAL                          DISCLOSURE OF CASH FLOW INFORMATION**           |   |                                        |            |                                        |   |  |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| Cash                          paid during the period for:                               |   |                                        |            |                                        |   |  |   |
| Income                          taxes                                              |   | $                                           | 6,035      |                                        | $      | - |   |
|                                                                                    |   |                                        |            |                                        |   |  |   |
| Interest                          expenses                                         |   | $                                           | 25,327     |                                        | $      | 1,954 |   |

----

**HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY, INC.**

**AND        SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**AS        OF SEPTEMBER 30, 2007 (UNAUDITED)**

**NOTE        1    ORGANIZATION AND BASIS OF PRESENTATION**

----

**HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY, INC.**

**AND        SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**AS        OF SEPTEMBER 30, 2007 (UNAUDITED)**

**NOTE        2**
**USE        OF ESTIMATES**

**NOTE        3**
**PRINCIPLES        OF CONSOLIDATION**

**NOTE        4**
**CASH        AND CASH EQUIVALENTS**

----

**HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY, INC.**

**AND        SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**AS        OF SEPTEMBER 30, 2007 (UNAUDITED)**

**NOTE        5**
**INCOME        TAXES**

**NOTE        6     EARNINGS PER SHARE**

**NOTE        7    BUSINESS SEGMENTS**

----

**HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY, INC.**

**AND        SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**AS        OF SEPTEMBER 30, 2007 (UNAUDITED)**

**NOTE        8     RECENT ACCOUNTING PRONOUNCEMENTS**

----

**HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY, INC.**

**AND        SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**AS        OF SEPTEMBER 30, 2007 (UNAUDITED)**

**NOTE        9     NOTES RECEIVABLE**

| Note                    receivable from a third party, interest rate of 12% per                             |   |   |         |   |
|-------------------------------------------------------------------------------------------------------------|--------|--------|---------|--------|
| annum,                    non-secured, due September 2007, was extended to December                    2007 |   | $      | 133,021 |   |
| Current                    maturities                                                                       |   | $      | 133,021 |   |

**NOTE        10     NOTES PAYABLE**

| Notes                    payable to a financial institution, interest rate of 9.6768%                    per      |   |         |    |
|-------------------------------------------------------------------------------------------------------------------|--------|--------------|---------|
| annum,                    secured by a director property and the company’s fixed                    assets, |   |    |    |
| guaranteed                    by a third party, due August 2007, was extend to June 2008                          |   | $            | 287,326 |   |
| Current                    maturities                                                                             |   | $            | 287,326 |   |

**NOTE        11   COMMITMENTS**

**Commitments**

**NOTE        12   RELATED PARTY TRANSACTIONS**

**NOTE        13   CONCENTRATIONS AND RISKS**

----

**Item        2. Management's Discussion and Analysis or Plan of        Operation.**

**SPECIAL        NOTE REGARDING FORWARD-LOOKING STATEMENTS**

**General**

----

**CRITICAL        ACCOUNTING POLICIES AND ESTIMATES**

----

**RESULTS        OF OPERATIONS**

| **Revenue**                                   |   | Three                  monthsended                  September 30,  |      | Increase/ |   |
|-----------------------------------------------|--------|-------------------------------------------------------------------------|-----------|-----------|--------|
| Product                                  |   | 2007                                                                    |      | 2006      |   | (Decrease)  |   |
|                                          |   |                                                                    |      |      |   |   |   |
| Pharmaceutical                  intermediates |   | $                                                                       | 834,766   |      | $      | 372,962 |   | $ | 461,804 |   |
| Pharmaceutical                  material      |   |                                                                    | 984,804   |      |   | 408,003 |   |   | 576,801 |   |
| Plant                  Extractive and others  |   |                                                                    | 126,405   |      |   | 35,128 |   |   | 91,277 |   |
| TOTAL                                         |   | $                                                                       | 1,945,975 |      | $      | 816,093 |   | $ | 1,129.882 |   |

| **Revenue**                              |   | Three                  months ended                  September 30, |      | Increase/ |   |
|-----------------------------------------------|--------|--------------------------------------------------------------------|-----------|-----------|--------|
| Product                                  |   | 2007                                                               |      | 2006      |   | (Decrease) |   |
| Pharmaceutical                  intermediates |   | $                                                                  | 584,423   |      | $      | 303,802 |   | $ | 280,621 |   |
| Pharmaceutical                  material      |   |                                                               | 737,037   |      |   | 347,097 |   |   | 389,940 |   |
| Plant                  Extractive and others  |   |                                                               | 109,295   |      |   | 21,542 |   |   | 87,753 |   |
| TOTAL                                         |   | $                                                                  | 1,430,755 |      | $      | 672,441 |   | $ | 758,314 |   |

----

|                                          |   | Nine                  months ended     |      |                               |   |
|-----------------------------------------------|--------|----------------------------------------|-----------|-------------------------------|--------|
|                                          |   | September                    30,  |      | Increase                    / |   |
| Product                                       |   | 2007                                   |      | 2006                     |   | (Decrease) |   |
| Pharmaceutical                  intermediates |   | $                                      | 2,090,216 |                          | $      | 915,706 |   | $ | 1,174,510 |   |
| Pharmaceutical                  material      |   |                                   | 2,543,828 |                          |   | 1,247,172 |   |   | 1,296,656 |   |
| Plant                  Extractive and others  |   |                                   | 320,078   |                          |   | 215,910 |   |   | 104,168 |   |
| TOTAL                                         |   | $                                      | 4,954,122 |                          | $      | 2,378,788 |   | $ | 2,575,334 |   |

|                                               |   | Nine                  months ended   |      |                          |   |
|-----------------------------------------------|--------|--------------------------------------|-----------|-------------------------------|--------|
|                                          |   |  September                  30, |      | Increase                    / |   |
| Product                                       |   | 2007                                 |      | 2006                          |   | (Decrease) |   |
| Pharmaceutical                  intermediates |   | $                                    | 1,383,161 |                          | $      | 736,471 |   | $ | 646,690 |   |
| Pharmaceutical                  material      |   |                                 | 1,799,362 |                          |   | 1,039,996 |   |   | 759,366 |   |
| Plant                  Extractive and others  |   |                                 | 280,121   |                          |   | 187,525 |   |   | 92,596 |   |
| TOTAL                                         |   | $                                    | 3,462,644 |                          | $      | 1,963,992 |   | $ | 1,498,652 |   |

*Cash*

*Working        Capital*

----

**INFLATION**

**CURRENCY          EXCHANGE FLUCTUATIONS**

All          of          our revenues and the majority of our expenses for the nine months ended          September 30, 2007 were denominated primarily in Renminbi ("RMB"), the          currency          of China, and was converted into US dollars at the exchange rate of 7.67576          to          1. Since July 22, 2005, the Renminbi has strengthened against the US dollars.          As          a result of the appreciation of RMB we recognized a foreign currency translation          gain of $252,634 during the first nine months of 2007. There could be no          assurance that RMB-to-U.S. dollar exchange rates will remain stable. A          devaluation of RMB relative to the U.S. dollar would adversely affect our          business, financial condition and results of operations. We do not engage          in          currency hedging.

**Item          3. Controls and Procedures**

|   | (a) | *Evaluation                    of disclosure controls and procedures*.                    Based on the evaluation of our disclosure controls and procedures                    (as                    defined in Securities Exchange Act of 1934 Rules 13a-15(e) and                    15d-15(e))                    required by Securities Exchange Act Rules 13a-15(b) or 15d-15(b),                    our                    Chief Executive Officer and Chief Financial Officer have concluded                    that as                    of the end of the period covered by this report, our disclosure                    controls                    and procedures were effective. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | *Changes                    in internal controls*.                    There were no changes in our internal control over financial                    reporting                    that occurred during our most recent fiscal quarter that have                    materially                    affected, or are reasonably likely to materially affect, our                    internal                    control over financial reporting. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**PART            II. OTHER INFORMATION**

**Item            1. Legal Proceedings:**

**Item            2 - Unregistered Sales of Equity Securities and Use of            Proceeds:**

**Item            3. Defaults Upon Senior Securities:**

**Item            4. Submission of Matters to a Vote of Security Holders:**

**Item            5. Other Information:**

**Item            6. Exhibits and Reports on Form 8-K**

| 31.1   |   | Sarbanes                      Oxley Section 302 Certification                      |
|--------|--------|------------------------------------------------------------------------------------|
|   |   |                                                                               |
| 31.2   |   | Sarbanes                      Oxley Section 302 Certification                      |
|   |   |                                                                               |
| 32.1   |   | Sarbanes                      Oxley Section 906 Certification                      |
|   |   |                                                                               |
| 32.2   |   | Sarbanes                      Oxley Section 906                      Certification |

----

|         |                                                         |                                             |
|--------------|--------------------------------------------------------------|--------------------------------------------------|
|         | HUIFENG                  BIO-PHARMACEUTICAL TECHNOLOGY, INC. |
|    |                                                    |                                        |
|              | By:                                                |  /s/  Jing                An Wang |
|         | Jing                  An Wang                                |
|         | Chief                  Executive Officer                     |

----